The information requested is shown in the table. For each of the appraisals, the table shows whether one or more Patient Access Schemes agreed between the Department of Health and the manufacturer have been considered by the National Institute for Health and Clinical Excellence (NICE).
Topic Start of NICE appraisal1 Date of final NICE guidance Recommendation Patient access scheme considered by NICE Yondelis (trabectedin) for soft tissue sarcoma September 2008 February 2010 Partial recommendation Yes Hycamtin (topotecan) for small cell lung cancer August 2008 November 2009 Partial recommendation No Hycamtin (topotecan) for Cervical Cancer (recurrent) December 2008 October 2009 Partial recommendation No Sutent (sunitinib) for Gastrointestinal stromal tumours August 2008 September 2009 Partial recommendation Yes Alimta (pemetrexed) for the first-line treatment of non- small-cell lung cancer October 2008 September 2009 Partial recommendation No Erbitux (cetuximab) for Colorectal Cancer (first line) January 2008 August 2009 Partial recommendation Yes Avastin (bevacizumab) (first-line), Nexavar (sorafenib) (first-line and second-line), Sutent (sunitinib) (second-line) and Torisel (temsirolimus) (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma September 20072 August 2009 Not recommended Nexavar (sorafenib) - yes Avastin (bevacizumab )-yes Sutent (sunitinib) - yes Mabthera (rituximab) for first-line treatment of chronic lymphocytic leukaemia September 2008 July 2009 Partial recommendation No Erbitux (cetuximab) for Head and Neck Cancer (squamous cell carcinoma) September 2008 June 2009 Not Recommended No Revlimid (lenalidomide) for Multiple Myeloma April 2008 June 2009 Partial recommendation Yes Sutent (sunitinib) for the first-line treatment of advanced and/or metastatic renal cell carcinoma September 20072 March 2009 Partial recommendation Yes Tarceva (erlotinib) for the treatment of non- small-cell lung cancer March 2006 November 2008 Partial recommendation Yes 1 The date NICE commenced work on the appraisal. NICE will also have carried out scoping work for the appraisal before this date. 2 This is the date on which the Multiple Technology Appraisal (MTA) began for Avastin (bevacizumab) (first-line), Nexavar (sorafenib) (first-line and second-line), Sutent (sunitinib) (first and second-line) and Torisel (temsirolimus) (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. The MTA was subsequently split and Sutent (sunitinib) for the first-line treatment of renal cell carcinoma was considered in a separate single technology appraisal.